Replies to post #231766 on Biotech Values

[jbog]

Do you think that this implies Gilead is gaining market share for some reason?

I find that hard to believe.

[DewDiligence]

ABBV’s 2Q20 Mavyret sales=$376M, -33% QoQ, -51% YoY—the decline was attributable to fewer new-patient starts during the COVID-19 pandemic:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2020-financial-results.htm

ABBV lowered full-year-2020 Mavyret sales to $2.1B (from the prior guidance of $2.3B), which implies 2H20 Mavyret sales of $1.0-1.1B.